Listen "Tackling Drug Resistance in Cancer Treatment – Stefanie Flückiger"
Episode Synopsis
Stefanie Flückiger, co-founder and CEO of Tolremo Therapeutics, is transforming cancer treatment with her innovative biotech company. Discover how Tolremo, an ETH spinoff, is tackling non-genetic drug resistance with cutting-edge technology. Hear about Stefanie's unique journey from academia to entrepreneurship, the impact of diversity in driving innovation, and the intriguing science behind cancer cells' resistance to drugs.This is her story.Chapters:(01:06) The Role of Awards and Female Leadership(03:52) Diversity in Leadership and Innovation(06:21) The Catalyst for Starting Tolremo(10:30) Understanding Cancer Cell Resistance(15:30) From Academia to Biotech: The Journey of Tolremo(19:47) Stephanie's Academic Background and ETH Experience(22:34) Closing Thoughts and Personal InsightsBooks mentioned:Why We Sleep by Matthew WalkerPodcast mentioned:Huberman Lab Podcast
More episodes of the podcast We Are ETH
Teaching Drones to See with Margarita Chli
09/05/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.